Protocols

Sanofi and Regeneron score early access for dupilumab in UK; Sanders skewers Sanofi on Zika vaccine

→ Sanofi and Regeneron have scored boasting rights for an early stamp of approval on their closely-watched eczema drug dupilumab. With a US approval looming, UK officials say they are providing early access to the drug ahead of an EMA decision. This drug is widely viewed as one of the top blockbusters in late-stage development.

→ Senator Bernie Sanders never keeps his contempt for pharma companies hidden. And he’s focused on Sanofi for his latest attack. The French pharma giant, he says, is on the verge of gaining a monopoly on the market for a Zika vaccine, but only with the considerable help of the US government, which bankrolled their research. Now in an op-ed for the New York Times, Sanders writes that he wants Sanofi to avoid its usual predatory practices and keep the vaccine cheap – but he’s not holding his breath.

→ Pacira Pharmaceuticals $PCRX says that its Phase IV study of Exparel (bupivacaine liposome injectable suspension) in patients undergoing total knee arthroplasty (TKA) achieved statistical significance for its co-primary endpoints for postsurgical pain and opioid reduction.


The best place to read Endpoints News? In your inbox.

Full-text daily reports for those who discover, develop, and market drugs. Join 17,000+ biopharma pros who read Endpoints News by email every day.

Free Subscription

RAPS Regulatory Convergence 2017